Dual Light Therapy Device for Dry Eye and OSD Management - Summary - MDSpire

Dual Light Therapy Device for Dry Eye and OSD Management

Essilor Instruments' eye-light® delivers targeted, condition-specific management for ocular surface diseases

  • June 2, 2026

  • 2 min

Share

Objective:

To introduce the eye-light® device for managing ocular surface diseases (OSD) and dry eye.

Key Findings:
  • Eye-light® has shown greater improvements in tear film quality and patient symptoms compared to IPL-only solutions.
  • The combination of light therapies is recognized in the TFOS DEWS III Management & Therapy Report as effective for managing OSD.
  • Clinical studies indicate superior efficacy of the combined therapies over long-term eye-drop therapy, improving tear stability and clinical outcomes.
  • Research shows long-lasting results maintained for up to 18 months.
Interpretation:

The all-in-one approach to light therapy aims to address the root causes of ocular surface diseases, enhancing patient management and experience.

Limitations:
Conclusion:

The introduction of eye-light® may lead to meaningful improvements in the quality of life for patients with dry eye disease.

Original Source(s)

Dual Light Therapy Device for Dry Eye and OSD Management

  • June 2, 2026

Related Content

Assessment of the aggregate index of systemic inflammation in dyslipidemia with dry eye disease: a retrospective case-control

Dry Eye Innovations

Himani Goyal, MD, discusses how advances in dry eye treatments have improved ophthalmic practice and outcomes.

  • May 1, 2026

  • 3 min
The Hormonal Link to Ocular Disease in Women

Neda Gioia, OD, CNS, FMCP, FOWNS, reviewed how levels of individual hormones and the balance between them help regulate tear production, inflammation, wound healing, lipid secretion, intraocular pressure (IOP), and neuroprotection, and therefore can result in a higher burden of dry eye, glaucoma, or retinal disease in women.